表紙
市場調查報告書

中風:開發中產品分析

Stroke - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 229744
出版日期 內容資訊 英文 673 Pages
訂單完成後即時交付
價格
Back to Top
中風:開發中產品分析 Stroke - Pipeline Review, H2 2019
出版日期: 2019年11月25日內容資訊: 英文 673 Pages
簡介

所謂中風是因為缺氧導致腦細胞死亡的症狀。症狀是會突然發生,並在短時間(通常數分到數小時)結束。最初患者會感到身體不適,臉色蒼白、精神非常差。還有可能產生突然性頭痛,或是突然臉部或手腳,尤其是身體一邊麻痺。口齒不清,或無法理解別人說話的內容、視力下降、走路難以保持平衡等症狀。

本報告提供全球各國治療中風所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

中風概要

治療藥的開發

治療藥的評估

開發治療藥的企業

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11524IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Stroke - Pipeline Review, H2 2019, provides an overview of the Stroke (Cardiovascular) pipeline landscape.

Stroke is a condition in which the brain cells suddenly die because of a lack of oxygen. Symptoms occur rapidly and usually last a short time, from a few minutes to a couple of hours. The symptoms of a stroke usually appear suddenly. Initially the person may feel sick, and look pale and very unwell. They may complain of a sudden headache. They may have sudden numbness in their face or limbs, particularly down one side of their body. They may appear confused and have trouble talking or understanding what is being said to them. They may have vision problems, and trouble walking or keeping their balance.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Stroke - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Stroke (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Stroke (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Stroke and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 13, 33, 24, 1, 3, 122, 17 and 2 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 31 and 5 molecules, respectively.

Stroke (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Stroke (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Stroke (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Stroke (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Stroke (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Stroke (Cardiovascular)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Stroke (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Stroke (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Stroke - Overview
  • Stroke - Therapeutics Development
  • Stroke - Therapeutics Assessment
  • Stroke - Companies Involved in Therapeutics Development
  • Stroke - Drug Profiles
  • Stroke - Dormant Projects
  • Stroke - Discontinued Products
  • Stroke - Product Development Milestones
  • Appendix

List of Tables

  • Table 1: Number of Products under Development for Stroke, H2 2019
  • Table 2: Number of Products under Development by Companies, H2 2019
  • Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Table 4: Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Table 5: Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
  • Table 6: Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019
  • Table 7: Number of Products under Development by Companies, H2 2019 (Contd..5), H2 2019
  • Table 8: Number of Products under Development by Companies, H2 2019 (Contd..6), H2 2019
  • Table 9: Number of Products under Development by Companies, H2 2019 (Contd..7), H2 2019
  • Table 10: Number of Products under Development by Companies, H2 2019 (Contd..8), H2 2019
  • Table 11: Number of Products under Development by Companies, H2 2019 (Contd..9), H2 2019
  • Table 12: Number of Products under Development by Universities/Institutes, H2 2019
  • Table 13: Number of Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
  • Table 14: Products under Development by Companies, H2 2019
  • Table 15: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Table 16: Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Table 17: Products under Development by Companies, H2 2019 (Contd..3), H2 2019
  • Table 18: Products under Development by Companies, H2 2019 (Contd..4), H2 2019
  • Table 19: Products under Development by Companies, H2 2019 (Contd..5), H2 2019
  • Table 20: Products under Development by Companies, H2 2019 (Contd..6), H2 2019
  • Table 21: Products under Development by Companies, H2 2019 (Contd..7), H2 2019
  • Table 22: Products under Development by Companies, H2 2019 (Contd..8), H2 2019
  • Table 23: Products under Development by Companies, H2 2019 (Contd..9), H2 2019
  • Table 24: Products under Development by Companies, H2 2019 (Contd..10), H2 2019
  • Table 25: Products under Development by Companies, H2 2019 (Contd..11), H2 2019
  • Table 26: Products under Development by Universities/Institutes, H2 2019
  • Table 27: Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
  • Table 28: Number of Products by Stage and Target, H2 2019
  • Table 29: Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
  • Table 30: Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
  • Table 31: Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019
  • Table 32: Number of Products by Stage and Target, H2 2019 (Contd..4), H2 2019
  • Table 33: Number of Products by Stage and Target, H2 2019 (Contd..5), H2 2019
  • Table 34: Number of Products by Stage and Mechanism of Action, H2 2019
  • Table 35: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
  • Table 36: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
  • Table 37: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019
  • Table 38: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..4), H2 2019
  • Table 39: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..5), H2 2019
  • Table 40: Number of Products by Stage and Route of Administration, H2 2019
  • Table 41: Number of Products by Stage and Molecule Type, H2 2019
  • Table 42: Stroke - Pipeline by Acorda Therapeutics Inc, H2 2019
  • Table 43: Stroke - Pipeline by Acticor Biotech SAS, H2 2019
  • Table 44: Stroke - Pipeline by Addex Therapeutics Ltd, H2 2019
  • Table 45: Stroke - Pipeline by advanceCor GmbH, H2 2019
  • Table 46: Stroke - Pipeline by AegisCN LLC, H2 2019
  • Table 47: Stroke - Pipeline by Aegle Therapeutics Corp, H2 2019
  • Table 48: Stroke - Pipeline by Affibody AB, H2 2019
  • Table 49: Stroke - Pipeline by Allife Medical Science and Technology Co Ltd, H2 2019
  • Table 50: Stroke - Pipeline by Allosteros Therapeutics Inc, H2 2019
  • Table 51: Stroke - Pipeline by Amarantus Bioscience Holdings Inc, H2 2019
  • Table 52: Stroke - Pipeline by Anavex Life Sciences Corp, H2 2019
  • Table 53: Stroke - Pipeline by Ankasa Regenerative Therapeutics Inc, H2 2019
  • Table 54: Stroke - Pipeline by Annovis Bio Inc, H2 2019
  • Table 55: Stroke - Pipeline by AntiRadical Therapeutics LLC, H2 2019
  • Table 56: Stroke - Pipeline by Antoxis Ltd, H2 2019
  • Table 57: Stroke - Pipeline by Apellis Pharmaceuticals Inc, H2 2019
  • Table 58: Stroke - Pipeline by Aposcience AG, H2 2019
  • Table 59: Stroke - Pipeline by APT Therapeutics Inc, H2 2019
  • Table 60: Stroke - Pipeline by AptaTargets SL, H2 2019

List of Figures

  • Figure 1: Number of Products under Development for Stroke, H2 2019
  • Figure 2: Number of Products under Development by Companies, H2 2019
  • Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
  • Figure 4: Number of Products by Top 10 Targets, H2 2019
  • Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019
  • Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Figure 8: Number of Products by Top 10 Routes of Administration, H2 2019
  • Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H2 2019
  • Figure 10: Number of Products by Top 10 Molecule Types, H2 2019
  • Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019
Back to Top